Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synovial Sarcoma X Breakpoint Protein 2 (SSX2)
- Target
- SSX2
- Molecular classification
- Transcription factor
01
Overview
Synovial sarcoma X breakpoint protein 2 (SSX2) is a member of the SSX family of transcriptional repressors implicated in chromosomal translocations, specifically the t(X;18) translocation found in synovial sarcomas. This translocation results in the fusion of the SYT gene with SSX genes, commonly SSX1 or SSX2, leading to the formation of an oncogenic fusion protein. SSX2 elicits immune responses in cancer patients, making it a potential target for cancer vaccine-based immunotherapy. Mutations such as fusions and other variants are observed in various cancers, including hematopoietic and lymphoid malignancies.
- Other names
- CT5.2CT5.2AHD21HOM-MEL-40SSX
02
Mechanism of action
SSX2 is not directly drugged; the fusion protein SYT-SSX is the target of interest, and immunotherapy strategies target aberrant expression patterns.
03
Biological functions
Transcriptional repressorProtein-protein interactionsImmune response
04
Disease associations
CancerHematopoietic and lymphoid malignancies
05
Safety considerations
Off-target effects of immunotherapyTumor lysis syndrome
06
Biomarkers
SSX2SYT-SSX fusion protein
Beyond the preview
Go deeper on Synovial Sarcoma X Breakpoint Protein 2 (SSX2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synovial Sarcoma X Breakpoint Protein 2 (SSX2).